King's College London

Research portal

Metformin in Pregnancy Study (MiPS): Protocol for a systematic review with individual patient data meta-analysis

Research output: Contribution to journalArticle

Standard

Metformin in Pregnancy Study (MiPS) : Protocol for a systematic review with individual patient data meta-analysis. / Mousa, Aya; Løvvik, Tone; Hilkka, Ijäs; Carlsen, Sven M.; Morin-Papunen, Laure; Tertti, Kristiina; Rönnemaa, Tapani; Syngelaki, Argyro; Nicolaides, Kypros; Shehata, Hassan; Burden, Christy; Norman, Jane E.; Rowan, Janet; Dodd, Jodie M.; Hague, William; Vanky, Eszter; Teede, Helena J.

In: BMJ Open, Vol. 10, No. 5, e036981, 21.05.2020.

Research output: Contribution to journalArticle

Harvard

Mousa, A, Løvvik, T, Hilkka, I, Carlsen, SM, Morin-Papunen, L, Tertti, K, Rönnemaa, T, Syngelaki, A, Nicolaides, K, Shehata, H, Burden, C, Norman, JE, Rowan, J, Dodd, JM, Hague, W, Vanky, E & Teede, HJ 2020, 'Metformin in Pregnancy Study (MiPS): Protocol for a systematic review with individual patient data meta-analysis', BMJ Open, vol. 10, no. 5, e036981. https://doi.org/10.1136/bmjopen-2020-036981

APA

Mousa, A., Løvvik, T., Hilkka, I., Carlsen, S. M., Morin-Papunen, L., Tertti, K., Rönnemaa, T., Syngelaki, A., Nicolaides, K., Shehata, H., Burden, C., Norman, J. E., Rowan, J., Dodd, J. M., Hague, W., Vanky, E., & Teede, H. J. (2020). Metformin in Pregnancy Study (MiPS): Protocol for a systematic review with individual patient data meta-analysis. BMJ Open, 10(5), [e036981]. https://doi.org/10.1136/bmjopen-2020-036981

Vancouver

Mousa A, Løvvik T, Hilkka I, Carlsen SM, Morin-Papunen L, Tertti K et al. Metformin in Pregnancy Study (MiPS): Protocol for a systematic review with individual patient data meta-analysis. BMJ Open. 2020 May 21;10(5). e036981. https://doi.org/10.1136/bmjopen-2020-036981

Author

Mousa, Aya ; Løvvik, Tone ; Hilkka, Ijäs ; Carlsen, Sven M. ; Morin-Papunen, Laure ; Tertti, Kristiina ; Rönnemaa, Tapani ; Syngelaki, Argyro ; Nicolaides, Kypros ; Shehata, Hassan ; Burden, Christy ; Norman, Jane E. ; Rowan, Janet ; Dodd, Jodie M. ; Hague, William ; Vanky, Eszter ; Teede, Helena J. / Metformin in Pregnancy Study (MiPS) : Protocol for a systematic review with individual patient data meta-analysis. In: BMJ Open. 2020 ; Vol. 10, No. 5.

Bibtex Download

@article{96ec5d4176944369b938cc08c161b83d,
title = "Metformin in Pregnancy Study (MiPS): Protocol for a systematic review with individual patient data meta-analysis",
abstract = "Introduction Gestational diabetes mellitus (GDM) is a common disorder of pregnancy and contributes to adverse pregnancy outcomes. Metformin is often used for the prevention and management of GDM; however, its use in pregnancy continues to be debated. The Metformin in Pregnancy Study aims to use individual patient data (IPD) meta-analysis to clarify the efficacy and safety of metformin use in pregnancy and to identify relevant knowledge gaps. Methods and analysis MEDLINE, EMBASE and all Evidence-Based Medicine will be systematically searched for randomised controlled trials (RCT) testing the efficacy of metformin compared with placebo, usual care or other interventions in pregnant women. Two independent reviewers will assess eligibility using prespecified criteria and will conduct data extraction and quality appraisal of eligible studies. Authors of included trials will be contacted and asked to contribute IPD. Primary outcomes include maternal glycaemic parameters and GDM, as well as neonatal hypoglycaemia, anthropometry and gestational age at delivery. Other adverse maternal, birth and neonatal outcomes will be assessed as secondary outcomes. IPD from these RCTs will be harmonised and a two-step meta-analytic approach will be used to determine the efficacy and safety of metformin in pregnancy, with a priori adjustment for covariates and subgroups to examine effect moderators of treatment outcomes. Sensitivity analyses will assess heterogeneity, risk of bias and the impact of trials which have not provided IPD. Ethics and dissemination All IPD will be deidentified and studies contributing IPD will have ethical approval from their respective local ethics committees. This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality. Findings will be published in peer-reviewed journals and disseminated at scientific meetings, providing much needed evidence to inform clinical and public health actions in this area.",
keywords = "diabetes in pregnancy, obstetrics, preventive medicine, reproductive medicine",
author = "Aya Mousa and Tone L{\o}vvik and Ij{\"a}s Hilkka and Carlsen, {Sven M.} and Laure Morin-Papunen and Kristiina Tertti and Tapani R{\"o}nnemaa and Argyro Syngelaki and Kypros Nicolaides and Hassan Shehata and Christy Burden and Norman, {Jane E.} and Janet Rowan and Dodd, {Jodie M.} and William Hague and Eszter Vanky and Teede, {Helena J.}",
year = "2020",
month = may,
day = "21",
doi = "10.1136/bmjopen-2020-036981",
language = "English",
volume = "10",
journal = "BMJ Open",
issn = "2044-6055",
number = "5",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Metformin in Pregnancy Study (MiPS)

T2 - Protocol for a systematic review with individual patient data meta-analysis

AU - Mousa, Aya

AU - Løvvik, Tone

AU - Hilkka, Ijäs

AU - Carlsen, Sven M.

AU - Morin-Papunen, Laure

AU - Tertti, Kristiina

AU - Rönnemaa, Tapani

AU - Syngelaki, Argyro

AU - Nicolaides, Kypros

AU - Shehata, Hassan

AU - Burden, Christy

AU - Norman, Jane E.

AU - Rowan, Janet

AU - Dodd, Jodie M.

AU - Hague, William

AU - Vanky, Eszter

AU - Teede, Helena J.

PY - 2020/5/21

Y1 - 2020/5/21

N2 - Introduction Gestational diabetes mellitus (GDM) is a common disorder of pregnancy and contributes to adverse pregnancy outcomes. Metformin is often used for the prevention and management of GDM; however, its use in pregnancy continues to be debated. The Metformin in Pregnancy Study aims to use individual patient data (IPD) meta-analysis to clarify the efficacy and safety of metformin use in pregnancy and to identify relevant knowledge gaps. Methods and analysis MEDLINE, EMBASE and all Evidence-Based Medicine will be systematically searched for randomised controlled trials (RCT) testing the efficacy of metformin compared with placebo, usual care or other interventions in pregnant women. Two independent reviewers will assess eligibility using prespecified criteria and will conduct data extraction and quality appraisal of eligible studies. Authors of included trials will be contacted and asked to contribute IPD. Primary outcomes include maternal glycaemic parameters and GDM, as well as neonatal hypoglycaemia, anthropometry and gestational age at delivery. Other adverse maternal, birth and neonatal outcomes will be assessed as secondary outcomes. IPD from these RCTs will be harmonised and a two-step meta-analytic approach will be used to determine the efficacy and safety of metformin in pregnancy, with a priori adjustment for covariates and subgroups to examine effect moderators of treatment outcomes. Sensitivity analyses will assess heterogeneity, risk of bias and the impact of trials which have not provided IPD. Ethics and dissemination All IPD will be deidentified and studies contributing IPD will have ethical approval from their respective local ethics committees. This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality. Findings will be published in peer-reviewed journals and disseminated at scientific meetings, providing much needed evidence to inform clinical and public health actions in this area.

AB - Introduction Gestational diabetes mellitus (GDM) is a common disorder of pregnancy and contributes to adverse pregnancy outcomes. Metformin is often used for the prevention and management of GDM; however, its use in pregnancy continues to be debated. The Metformin in Pregnancy Study aims to use individual patient data (IPD) meta-analysis to clarify the efficacy and safety of metformin use in pregnancy and to identify relevant knowledge gaps. Methods and analysis MEDLINE, EMBASE and all Evidence-Based Medicine will be systematically searched for randomised controlled trials (RCT) testing the efficacy of metformin compared with placebo, usual care or other interventions in pregnant women. Two independent reviewers will assess eligibility using prespecified criteria and will conduct data extraction and quality appraisal of eligible studies. Authors of included trials will be contacted and asked to contribute IPD. Primary outcomes include maternal glycaemic parameters and GDM, as well as neonatal hypoglycaemia, anthropometry and gestational age at delivery. Other adverse maternal, birth and neonatal outcomes will be assessed as secondary outcomes. IPD from these RCTs will be harmonised and a two-step meta-analytic approach will be used to determine the efficacy and safety of metformin in pregnancy, with a priori adjustment for covariates and subgroups to examine effect moderators of treatment outcomes. Sensitivity analyses will assess heterogeneity, risk of bias and the impact of trials which have not provided IPD. Ethics and dissemination All IPD will be deidentified and studies contributing IPD will have ethical approval from their respective local ethics committees. This study will provide robust evidence regarding the efficacy and safety of metformin use in pregnancy, and may identify subgroups of patients who may benefit most from this treatment modality. Findings will be published in peer-reviewed journals and disseminated at scientific meetings, providing much needed evidence to inform clinical and public health actions in this area.

KW - diabetes in pregnancy

KW - obstetrics

KW - preventive medicine

KW - reproductive medicine

UR - http://www.scopus.com/inward/record.url?scp=85085472226&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2020-036981

DO - 10.1136/bmjopen-2020-036981

M3 - Article

C2 - 32444434

AN - SCOPUS:85085472226

VL - 10

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 5

M1 - e036981

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454